TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) ROCE % : -107.20% (As of Sep. 2016)

View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TetraLogic Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2016 was -107.20%.

TetraLogic Pharmaceuticals ROCE % Historical Data

The historical data trend for TetraLogic Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals ROCE % Chart

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

ROCE %

-147.08

-220.57

-65.67

-40.23

-50.44

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
ROCE %	Get a 7-Day Free Trial														-41.03	-68.21	-66.46	-43.84	-107.20

TetraLogic Pharmaceuticals ROCE % Calculation

TetraLogic Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2015 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2015 )		(A: Dec. 2014 )		(A: Dec. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2015 )		(A: Dec. 2014 )		(A: Dec. 2015 )
	=	-43.34	/	( ( (116.616 - 5.122)	+	(64.021 - 3.66) )	/ 2 )
	=	-43.34	/	( (111.494	+	60.361)	/ 2 )
	=	-43.34	/	85.9275
	=	-50.44 %

TetraLogic Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2016 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2016 )		(Q: Jun. 2016 )		(Q: Sep. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2016 )		(Q: Jun. 2016 )		(Q: Sep. 2016 )
	=	-36.772	/	( ( (51.057 - 11.905)	+	(42.788 - 13.334) )	/ 2 )
	=	-36.772	/	( ( 39.152	+	29.454 )	/ 2 )
	=	-36.772	/	34.303
	=	-107.20 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2016) EBIT data.

TetraLogic Pharmaceuticals (OTCPK:TLOG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TetraLogic Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Phoenixville Pike, Malvern, PA, USA, 19355

Website

http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.

Executives

Hudson Bay Capital Management Lp	other: See Remarks	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc	other: See Remarks	30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc	other: See Remarks	1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc	other: See Remarks	277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber	other: See Remarks	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison	officer: CFO & Treasurer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon	10 percent owner	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines